Glycobia is committed to rapidly commercializing new and affordable biotherapeutic drugs synthesized from the bottom-up.

Glycobia employs proprietary BUG™ (bottom-up glycoengineering) technology to design bacteria that produce novel and enhanced biotherapeutics to address unmet medical needs.

February 9, 2012

Glycobia is Cornell University's inaugural resident of the Kevin M. McGovern Family Center for Venture Development in the Life Sciences.

September 15, 2011

Glycobia awarded SBIR Phase II Grant from the National Institutes of Health.